Nine children were successfully treated for osteoid osteoma, a benign bone tumor, by doctors from Children’s National Health System in Washington, DC. The completion of the clinical trial marks a triumph for the new, noninvasive treatment method called magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU). This incisionless surgery is safe, painless, and does no collateral damage to surrounding tissues compared to invasive surgeries. MR-HIFU ablation uses focused ultrasound waves under MR guidance to precisely target tumors and destroy them without the need for needles or scalpels.
In the new study published in the Journal of Pediatrics, MR-HIFU delivered using Philips Sonalleve V2 device integrated with the company’s Achieva 1.5T MRI was compared to radiofrequency ablation (RFA) for treating painful osteoid osteoma in pediatric patients. The results of the study showed that the new method is a feasible and safe alternative to RFA, which requires incisions and exposure to ionizing radiation. The nine children treated with MR-HIFU at Children’s National, the first US hospital to use the novel treatment, did not have any serious adverse reactions and showed a good clinical response.
“Our objective is to provide a noninvasive treatment option for children with osteoid osteoma and we’re very pleased with the results of this clinical trial,” says Karun Sharma, M.D., Ph.D., director of Interventional Radiology at Children’s National and principal investigator for the osteoid osteoma trial. “We have now shown that MR-HIFU can be performed safely with clinical improvement that is comparable to RFA, but without any incisions or ionizing radiation exposure to children.”
Study in Journal of Pediatrics: Comparison of Noninvasive High-Intensity Focused Ultrasound with Radiofrequency Ablation of Osteoid Osteoma…
Product page: Sonalleve MR-HIFU…
Via: Children’s National…